Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122617) titled 'Efficacy and Safety of Zuberitamab Combined with Pola-CHP Regimen in the Treatment of B-Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis' on April 15.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Condition:
B-cell lymphoma-related hemophagocytic syndrome
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-05-01
Target Sample Size: Zuberitamab group:22;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=313080
Published by H...